retatrutide trial news Weight Loss Results:Trial Data and FDA Status BREAKING NEWS: Retatrutide Clears Crucial
Description
Retatrutide activates three metabolic receptors: GLP-1, GIP, and glucagon
The GLP-1 appetite suppression effect makes this worse
New neurological symptoms : Numbness, weakness, loss of sensation, or difficulty walking may indicate peripheral neuropathy or other neurological conditions requiring investigation
The most pronounced differences were observed in gastrointestinal and metabolic events: nausea (combination: n = 9651 vs monotherapy: n = 38,030), vomiting (4383 vs 17,062), pancreatitis (1389 vs 6655), and hypoglycemia (773 vs 1778)
2016;129(4):407415.e4
